PharMingen Sustainability Profile
PharMingen, a division of BD Biosciences, is a leading player in the biotechnology industry, headquartered in the United States. Established in the early 1990s, the company has made significant strides in the development of innovative solutions for cell biology and immunology research. With a strong focus on flow cytometry, PharMingen offers a comprehensive range of reagents, instruments, and software that are essential for advanced cellular analysis. Renowned for its high-quality monoclonal antibodies and unique assay kits, PharMingen stands out in the market for its commitment to scientific excellence and customer support. The company has achieved notable recognition for its contributions to research and diagnostics, solidifying its position as a trusted partner for laboratories worldwide. With a robust presence in North America and Europe, PharMingen continues to drive advancements in life sciences, empowering researchers to unlock new discoveries.
DitchCarbon Score
How does PharMingen's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
PharMingen's score of 67 is higher than 79% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
PharMingen, headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Becton, Dickinson and Company, which may influence its climate commitments and reporting practices. PharMingen's climate initiatives and reduction targets are inherited from its parent company, Becton, Dickinson and Company. This includes participation in various sustainability initiatives such as the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP). However, specific reduction targets or achievements for PharMingen itself are not detailed. As part of its corporate family, PharMingen aligns with Becton, Dickinson and Company's broader climate strategies, which may include commitments to reduce emissions across Scope 1, 2, and 3 categories. Nonetheless, without specific data or targets available for PharMingen, the company's individual climate commitments remain unclear.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 96,333,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 514,801,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | 158,622,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | - | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
How Carbon Intensive is PharMingen's Industry?
How Carbon Intensive is PharMingen's Location?
PharMingen's Scope 3 Categories Breakdown
PharMingen's Scope 3 emissions, which decreased by 6% last year and increased significantly since 2008, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 38% of Scope 3 emissions.
Top Scope 3 Categories
PharMingen's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
PharMingen has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Beckman Coulter, Inc.
Miltenyi Biotec
Let us know if this data was useful to you
Usage Policy
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.